Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
56.12
+0.64 (1.15%)
Dec 20, 2024, 4:00 PM EST - Market closed
Rhythm Pharmaceuticals Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for RYTM stock have an average target of 65.8, with a low estimate of 52 and a high estimate of 80. The average target predicts an increase of 17.25% from the current stock price of 56.12.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for RYTM stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 5 | 6 | 6 |
| Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 8 | 9 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Initiates $76 | Buy | Initiates | $76 | +35.42% | Dec 20, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $59 → $66 | Strong Buy | Maintains | $59 → $66 | +17.61% | Dec 5, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $69 | Strong Buy | Reiterates | $69 | +22.95% | Dec 4, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $69 | Strong Buy | Reiterates | $69 | +22.95% | Nov 25, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $80 | Strong Buy | Maintains | $80 | +42.55% | Nov 19, 2024 |
Financial Forecast
Revenue This Year
126.70M
from 77.43M
Increased by 63.64%
Revenue Next Year
181.16M
from 126.70M
Increased by 42.98%
EPS This Year
-4.43
from -3.20
EPS Next Year
-2.70
from -4.43
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 131.8M | 219.0M | 420.0M | |||
| Avg | 126.7M | 181.2M | 325.3M | |||
| Low | 120.7M | 161.4M | 214.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 70.2% | 72.9% | 131.8% | |||
| Avg | 63.6% | 43.0% | 79.6% | |||
| Low | 55.9% | 27.4% | 18.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -4.22 | -2.13 | 0.02 | |||
| Avg | -4.43 | -2.70 | -1.01 | |||
| Low | -4.53 | -3.10 | -2.76 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.